Skip to main content
TrimSoMoEverything GLP-1, in one place
← All medications

FDA-approved medication

Saxenda (liraglutide)

Key facts

Last reviewed: 2026-11-08
  • •FDA label says "SAXENDA (liraglutide) injection, for subcutaneous use".
  • •FDA label says "Inject SAXENDA subcutaneously in the abdomen, thigh, or upper arm once daily at any time of day, without regard to the timing of meals."
  • •FDA label says "SAXENDA is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: • Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. ( 1 ) • Adults with overweight in the presence of at least one weight-related comorbid condition."
  • •FDA label says "The recommended dose of SAXENDA is 3 mg daily. ( 2.2 ) • Initiate at 0.6 mg per day for one week. In weekly intervals, increase the dose until a dose of 3 mg is reached."

FDA-approved to reduce excess body weight and maintain weight reduction long term. Read the dose schedule and safety information, and check the official prescribing information. Confirm costs and coverage with your pharmacy, insurer, or the manufacturer.

liraglutide · 18 mg/3 mL (6 mg/mL) pre-filled pen · once daily, subcutaneous

Active ingredient
liraglutide
Dosage form (label)
Injection: 18 mg/3 mL (6 mg/mL) pre-filled pen
Schedule (label)
Once daily, subcutaneous
Strengths (label)
Injection: 18 mg/3 mL (6 mg/mL) solution in a pre-filled multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg. Injected subcutaneously once daily.DailyMed FDA Prescribing Information (NDA 206321) · Saxenda official website. Accessed November 8, 2026.
Manufacturer
Novo Nordisk A/S (per label)

Brand names are trademarks of their respective owners; this site is not affiliated with them.

Illustration of a simplified clay injection pen on a saucer beside a daily calendar card

FDA label

Saxenda dose steps (FDA label)

  1. 0.6 mg
    Week 1
    Starting dose (daily)
  2. 1.2 mg
    Week 2
    Dose escalation (daily)
  3. 1.8 mg
    Week 3
    Dose escalation (daily)
  4. 2.4 mg
    Week 4
    Dose escalation (daily)
  5. 3 mg
    Week 5 onward
    Recommended maintenance dosage
Per FDA label. Your prescriber sets your dose. Inject SAXENDA subcutaneously once daily at any time of day, without regard to the timing of meals. The recommended dosage of SAXENDA is 3 mg daily. For adults, lower dosages are for titration only; discontinue SAXENDA if the patient cannot tolerate the 3 mg dosage or has not lost at least 4% of baseline body weight by 16 weeks. For pediatric patients aged 12 and older, recommended maintenance dosage is 3 mg daily (or 2.4 mg if 3 mg is not tolerated); discontinue if pediatric patient has not had a reduction in BMI of at least 1% from baseline after 12 weeks on maintenance.

FDA label answers

Common questions about Saxenda

All answers are taken directly from the official FDA prescribing information (FDA Prescribing Information (DailyMed setid 3946d389-0926-4f77-a708-0acb8153b143, SPL version 22, revised 06/2026)).

Who is Saxenda approved for?

FDA label says "SAXENDA is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: • Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. ( 1 ) • Adults with overweight in the presence of at least one weight-related comorbid condition."

How often is Saxenda taken?

FDA label says "Inject SAXENDA subcutaneously in the abdomen, thigh, or upper arm once daily at any time of day, without regard to the timing of meals."

What are the most common side effects listed on the label for Saxenda?

FDA label says "Most common adverse reactions, reported in greater than or equal to 5% are: nausea, diarrhea, constipation, vomiting, injection site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, upper abdominal pain, pyrexia, and gastroenteritis."

Is there a boxed warning on the Saxenda label?

Yes. FDA label says "WARNING: RISK OF THYROID C-CELL TUMORS" — "Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice."

What is the recommended maintenance dose for Saxenda?

FDA label says "The recommended dose of SAXENDA is 3 mg daily. ( 2.2 ) • Initiate at 0.6 mg per day for one week. In weekly intervals, increase the dose until a dose of 3 mg is reached."

Patient Consultation & Copay Protocol

Next Steps: Evaluating Saxenda for Your Care Plan

Transition from drug facts to clinical action. Estimate potential out-of-pocket expenses, generate consultation questions, and verify eligibility.

All Decision Tools
Copay & Savings Card

Out-of-Pocket Expense Modeling

Estimate what you might pay each month based on manufacturer assistance terms and employer benefit design.

Covered Commercial: Varies by commercial formulary tiering (as low as $25 / month with card)
Uncovered Commercial: Approx. $700 – $900 / month with manufacturer assistance
Self-Pay Option: Retail cash list reference (~$1,349); generic versions under development
Medicare: Standard Medicare Part D excludes weight loss therapy
Clinical Readiness

Consultation & Lab Checklist

Arrive at your appointment prepared with essential baseline bloodwork requirements and contraindication screens.

Required Bloodwork: Baseline renal profile, lipase/pancreatitis history, and thyroid evaluation
Safety Screening: Screening for personal/family history of MTC, MEN 2, pancreatitis, and gallbladder disease.
Clinical Format: Includes 12 essential lab panels and formatted physician questions.
Eligibility & Providers

BMI Qualification & Directory

Verify your body mass index against official FDA prescribing label requirements and locate qualified clinicians.

FDA Label Threshold: BMI ≥30 kg/m², or ≥27 kg/m² with at least one metabolic health comorbidity

Editorial & Regulatory Standard: TrimSoMo is an independent, non-commercial healthcare information platform. Estimated out-of-pocket costs and savings card parameters reflect publicly published 2026 manufacturer program guidelines and do not guarantee individual insurance coverage or pharmacy dispensing prices. Prescriptions require clinical evaluation by a licensed physician.

Before Starting Saxenda

Gradual Dose Titration

Per the FDA label, doses start low and increase over several months to help reduce gastrointestinal side effects. Your clinician sets your schedule. Review post-marketing data in our GLP-1 side effects from FDA labels → FAERS reports do not prove cause.

Lifestyle & Nutrition Support

In clinical studies, medication was used together with a reduced-calorie diet and increased physical activity.

Long-Term Plan

Talk with your clinician before changing or stopping treatment.

Future Pharmacotherapy Outlook

Exploring non-injectable options?

Some oral GLP-1 medicines are FDA-approved and others are still in development. The list shows each medicine's status and source.

Oral GLP-1 medicines: see which are FDA-approved and which are still in development →